{"id":"W3132700492","doi":"10.1158/1538-7445.sabcs20-pd2-04","title":"Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Letrozole; Internal medicine; Anastrozole; Oncology; Tamoxifen; Hazard ratio; Placebo; Randomized controlled trial; Progression-free survival; Goserelin; Breast cancer; Chemotherapy; Gynecology; Cancer; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003040839,0.0008021256,0.001092066,0.0004227698,0.0002932666,0.001185996,0.0008527503,0.0006303032,0.006802919],"category_scores_gemma":[0.002169356,0.0003089254,0.00162953,0.0006768439,0.0004063034,0.000642349,0.0006048653,0.002040639,0.001063281],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007864798,"about_ca_system_score_gemma":0.001074268,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007045611,"about_ca_topic_score_gemma":0.002575559,"domain_scores_codex":[0.9988554,0.0006228549,0.00006661937,0.0001727497,0.0001736701,0.0001088122],"domain_scores_gemma":[0.9988198,0.0002586882,0.0003744486,0.0001642222,0.0001526988,0.000230129],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7444173,0.003858834,0.02510683,0.002997277,0.008695456,0.0001394376,0.0001503126,0.002358625,0.01317493,0.000428505,0.03324203,0.1654306],"study_design_scores_gemma":[0.5857009,0.1301998,0.1924398,0.0005956381,0.01787828,0.000788113,0.0001708589,0.002282926,0.009413175,0.001156527,0.05921739,0.0001566066],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8664085,0.02385195,0.00279597,0.0027678,0.0007433501,0.004357545,0.07460362,0.000542254,0.02392904],"genre_scores_gemma":[0.9064851,0.00373762,0.002203013,0.002916317,0.0005278872,0.003876256,0.07083745,0.0001222509,0.009294006],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006802919,"threshold_uncertainty_score":0.02275801,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04548641285416216,"score_gpt":0.3831915911177023,"score_spread":0.3377051782635401,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}